A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment

NCT07413042 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

SCLC, Extensive Stage

Interventions

DRUG: [225Ac]Ac-DOTATATE

Sponsor

Peking University Cancer Hospital & Institute